|
Bibliografía:
1.
Russell James. Managment of sepsis. N Engl J Med
2006; 355:1699-1713.
2.
PROWESS Study Group. Efficacy and safety of
recombinant human activated protein C for severe
sepsis. N Engl J Med 2001;344:699-709.
3.
Dellinger P. et al. Surviving Sepsis Campaign
guidelines for management of severe sepsis and septic
shock. Crit Care Med 2004; 32:858-873.
4.
ADRESS Study Group. Drotrecogin alfa for adults
with severe sepsis and low risk of death. N Engl J Med
2005; 353:1332-1341.
5.
Rivers E et al. Early goal- directed therapy in
the treatment of severe sepsis and septic shock. N Engl
J Med 2001; 345:1368-1377.
6.
Patel et al. New treatment strategies for severe
sepsis and septic shock. Curr Op in Crit Care 2003;
9:390-396.
7.
Bernard GR et al. Extended evaluation of recombinant
human activated protein C United States Trial. Phase 3b,
Multicenter study of drotrecogin alfa in severe sepsis
(ENHANCE US).
Chest 2004;125:2206-2216.
8.
Ananne et al. Septic Shock. Lancet 2005;
365:63-76.
9.
Minecci et al.
Meta- Analysis: The effect of steroids on survival and
shock during sepsis depnds on the dose. Annals of
Internal Medicine 2004; 141:47-72.
10.
Nguyen et al. Severe sepsis and septic shock:
Review of the literature and Emergency Department
management guidelines. Annals of Emergency Medicine
2006; 48:29-54.
11.
Gullo et al. Management of severe sepsis and
septic shock: challenges and recommendations. Crit Care
Clin 2006; 22:489-501.
12.
Hurtado et al. The rol of bundles in sepsis care.
Crit Care Clin 2006; 22:521-529.
13.
Van der Berghe et al.
Intensive insulin Therapy in the medical ICU. N Engl J
Med 2006; 354:449-461.
14.
Van der Berghe et al. Intensive insulin therapy
in critically ill patients. N Engl J Med 2001;
345:1359-1367.
15.
Angstwurm M et al. Selenium in Intensive Care:
Results of a prospective randomized, placebo-
controlled, multiple-center study in patients with
severe systemic inflamatory response syndrome, sepsis
and septic shock. Crit Care Med 2007; 35:118-126. |
